Medicina
Fachbereich
University of Freiburg
Friburgo de Brisgovia, AlemaniaPublikationen in Zusammenarbeit mit Forschern von University of Freiburg (12)
2021
-
A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: The SynapSES trial
Journal of Parkinson's Disease, Vol. 11, Núm. 1, pp. 187-198
2019
-
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2)
Nature Genetics
-
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing
Nature Genetics, Vol. 51, Núm. 3, pp. 414-430
-
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients
Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106
2018
-
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance
Genes Chromosomes and Cancer, Vol. 57, Núm. 11, pp. 547-556
2013
-
Monosomal karyotype in MDS: Explaining the poor prognosis
Leukemia, Vol. 27, Núm. 10, pp. 1988-1995
2012
-
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge
Journal of Clinical Oncology, Vol. 30, Núm. 8, pp. 820-829
2011
-
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease
Nature Genetics, Vol. 43, Núm. 5, pp. 429-436
-
Device therapy and hospital reimbursement practices across European countries: A heterogeneous scenario
Europace, Vol. 13, Núm. SUPPL. 2
2010
-
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
The Lancet Oncology, Vol. 11, Núm. 6, pp. 521-529
2006
-
The malignant potential of a succinate dehydrogenase subunit B germline mutation
Journal of Endocrinological Investigation, Vol. 29, Núm. 4, pp. 350-352